Limit the spread of infection
Clostridium difficile (C. diff) is the most common healthcare-associated infection, causing antibiotic-associated diarrhea that may lead to pseudomembranous colitis and even death. C. diff has an enormous impact on healthcare systems worldwide. An estimated 124,0001 cases of Clostridium difficile infection (CDI) occur annually in Europe, costing the EU up to €3 billion per year.2
The innovative cobas® Cdiff test lets you keep a closer eye on at-risk patients. Detect C. diff from unformed stool specimens, deliver definitive results to inform timely treatment, and take appropriate measures for isolation and prevention to limit the spread of infection.
Speed and accuracy
Definitive results with a 20 minute turnaround time.
Ease of use
Simplified workflow, reduced hands-on time (less than a minute with no vortex or precision pipetting required) and easy result interpretation.
Flexibility & accessibility
Small, compact design that is suitable for STAT or out-of-hours locations, delivering definitive results for time-sensitive treatment and prevention.
Intended use for cobas® Cdiff
The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridium difficile (C. difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.
This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.